MARKET

TYME

TYME

Tyme Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.290
-0.030
-2.27%
After Hours: 1.270 -0.02 -1.55% 18:58 06/18 EDT
OPEN
1.300
PREV CLOSE
1.320
HIGH
1.310
LOW
1.280
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
4.990
52 WEEK LOW
0.8500
MARKET CAP
222.15M
P/E (TTM)
-5.9201
1D
5D
1M
3M
1Y
5Y
Bionano Genomics to join Russel 3000 Index, while AcelRx Pharmaceuticals to see deletion among healthcare stocks
At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen
Seekingalpha · 6d ago
Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 6d ago
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share.
Benzinga · 6d ago
Tyme Stock Is Trading Higher On Pipeline Update After Strategic Review, Q4 Earnings
Benzinga · 06/11 11:26
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 06/10 22:55
Tyme Technologies rises on pipeline update
MicroStockHub/E+ via Getty Images Tyme Technologies (TYME) has risen ~13.2% in extended trading after announcing  Q4 and full year financials for fiscal 2021 today. The basic and diluted loss per share has
Seekingalpha · 06/10 21:03
BRIEF-Tyme Technologies Inc Reports Fiscal Year 2021 Financial Results
reuters.com · 06/10 20:18
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results
--- Recently appointed acting Chief Medical Officer and incoming Chief Financial Officer bolster leadership team expertise
Business Wire · 06/10 20:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TYME. Analyze the recent business situations of Tyme Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TYME stock price target is 9.50 with a high estimate of 9.50 and a low estimate of 9.50.
EPS
Institutional Holdings
Institutions: 110
Institutional Holdings: 22.15M
% Owned: 12.87%
Shares Outstanding: 172.21M
TypeInstitutionsShares
Increased
29
5.52M
New
15
639.60K
Decreased
15
923.12K
Sold Out
5
172.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.57%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Chairman/Chief Scientific Officer/Director
Steve Hoffman
Chief Executive Officer/Director
Richard Cunningham
Chief Financial Officer
Frank Porfido
Chief Operating Officer
Michele Korfin
Other
Jonathan Eckard
Other
Jan Van Tornout
Secretary
James Biehl
Independent Director
David Carberry
Independent Director
Donald Degolyer
Independent Director
Douglas Michels
Independent Director
Gerald Sokol
Independent Director
Paul Sturman
Independent Director
Timothy Tyson
No Data
About TYME
TYME Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. The Company’s lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. SM-88 is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. The Company has multiple cancer metabolism-based assets and other formulations for SM-88 in the pipeline, including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting.

Webull offers kinds of Tyme Technologies Inc stock information, including NASDAQ:TYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TYME stock methods without spending real money on the virtual paper trading platform.